Literature DB >> 3531118

The use of non-hypoxic cell sensitizers in radiobiology and radiotherapy.

J B Mitchell, A Russo, T J Kinsella, E Glatstein.   

Abstract

Many different non-hypoxic cell radiosensitizers have been identified over the years. Radiosensitization by these agents is mediated through a variety of mechanisms, including inhibition of repair (both enzymatic and chemical), modification in the DNA molecule, and perturbation and redistribution in the cell cycle. Recent clinical interest in the use of halogenated pyrimidines as radiosensitizers has prompted a number of questions requiring both laboratory and clinical research to maximize this therapeutic approach. Other radiosensitizers that alter cellular redox processes in different ways are discussed in the context of better understanding the cellular biochemical systems that are affected in aerobic radiosensitization. Advancement in the use of non-hypoxic cell sensitizers in radiation cancer treatment will most likely depend on a knowledge of the detailed biochemical mechanisms of these agents and how they might be used to exploit any subtle biochemical differences between tumor and normal tissue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531118     DOI: 10.1016/0360-3016(86)90206-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

Review 1.  Photodynamic therapy in the treatment of cancer: current state of the art.

Authors:  R A Hsi; D I Rosenthal; E Glatstein
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 2.  The application of 5-bromodeoxyuridine in the management of CNS tumors.

Authors:  A Freese; D O'Rourke; K Judy; M J O'Connor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Tumour proliferation assessed by combined histological and flow cytometric analysis: implications for therapy in squamous cell carcinoma in the head and neck.

Authors:  M H Bennett; G D Wilson; S Dische; M I Saunders; C A Martindale; B M Robinson; A E O'Halloran; M D Leslie; J H Laing
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.